CAS 114899-77-3
:Trabectedina
Descripción:
Trabectedina, también conocido por su código de desarrollo ET-743, es un alcaloide sintético derivado de la tunicada marina Ecteinascidia turbinata. Se utiliza principalmente como agente antineoplásico en la terapia del cáncer, particularmente para sarcomas de tejidos blandos y cáncer de ovario. Trabectedina funciona al unirse al ADN y alterar el proceso de transcripción, lo que lleva a la detención del ciclo celular y apoptosis en las células cancerosas. Su mecanismo de acción implica la formación de aductos de ADN, que interfieren con la función normal de la maquinaria celular. El compuesto exhibe una estructura única caracterizada por un núcleo policíclico complejo y una cadena lateral funcionalizada, lo que contribuye a su actividad biológica. Trabectedina se administra por vía intravenosa y tiene un perfil farmacocinético específico, que incluye una vida media relativamente corta y una extensa unión a proteínas. Los efectos secundarios pueden incluir mielosupresión, elevación de enzimas hepáticas y trastornos gastrointestinales. Debido a su origen y mecanismo únicos, Trabectedina representa un avance significativo en las terapias dirigidas contra el cáncer, destacando el potencial de los compuestos derivados del mar en la química medicinal.
Fórmula:C39H43N3O11S
InChI:InChI=1/C40H45N3O11S/c1-17-11-21-12-23-38(47)43-24-15-51-39(48)40(22-14-26(49-5)25(45)13-20(22)7-9-41-40)8-10-55-37(31(43)30(42(23)4)27(21)32(46)33(17)50-6)29-28(24)36-35(52-16-53-36)18(2)34(29)54-19(3)44/h11,13-14,23-24,30-31,37-38,41,45-47H,7-10,12,15-16H2,1-6H3/t23-,24-,30+,31+,37+,38-,40+/m0/s1
Clave InChI:InChIKey=PKVRCIRHQMSYJX-AIFWHQITSA-N
SMILES:O[C@@H]1N2[C@@]([C@]3(C=4C([C@@]2(COC(=O)[C@@]5(CS3)C=6C(=CC(O)=C(OC)C6)CCN5)[H])=C7C(=C(C)C4OC(C)=O)OCO7)[H])([C@]8(C=9C(C[C@@]1(N8C)[H])=CC(C)=C(OC)C9O)[H])[H]
Sinónimos:- (1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-Trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro(6,16-(epithiopropanooxymethano)-7,13-imino-6aH-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-5-yl acetate
- (1′R,6R,6aR,7R,13S,14S,16R)-5-(Acetyloxy)-3′,4′,6,6a,7,13,14,16-octahydro-6′,8,14-trihydroxy-7′,9-dimethoxy-4,10,23-trimethylspiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′(2′H)-isoquinolin]-19-one
- 1,3-Benzodioxole-5-propanoic acid,7-methyl-6-(phenylmethoxy)-α-[[(phenylmethoxy)carbonyl]amino]-,2,2-dimethoxyethyl ester
- Ccris 8133
- Ect 743
- Ecteinascidin
- Ecteinascidine 743
- Et-743
- Nsc 648766
- Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6R-(6-alpha,6a-beta,7-beta,13-beta,14-beta,16-alpha,20R*))-
- Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)-
- Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′(2′H)-isoquinolin]-19-one, 5-(acetyloxy)-3′,4′,6,6a,7,13,14,16-octahydro-6′,8,14-trihydroxy-7′,9-dimethoxy-4,10,23-trimethyl-, (1′R,6R,6aR,7R,13S,14S,16R)-
- Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′(2′H)-isoquinolin]-19-one, 5-(acetyloxy)-3′,4′,6,6a,7,13,14,16-octahydro-6′,8,14-trihydroxy-7′,9-dimethoxy-4,10,23-trimethyl-, [6R-(6α,6aβ,7β,13β,14β,16α,20R*)]-
- Trabectedin
- Unii-Id0Yzq2Tcp
- Yondelis
- ecteinascidin 743
- ecteinascidin 743,Trabectedin,ET 743
- Trabectedin Q: What is the storage condition of
- PKVRCIRHQMSYJX-ZKZLGIKISA-N
- (1'R,6R,6aR,7R,13S,14S,16R)-
- Trabectedin Q: What is the CAS Number of
- ASMF Filed
- NSC-684766
- ECTEINASCIDIN 743; ET-743; ECTEINASCIDIN
- Trabectedin (Ecteinascidin 743)
- Trabectedin Q: What are the applications of
- Trabectedin (Yondelis)
- Yondelis R ,Trabectedin
- TrabectedinQ: What is
- Trabectedin(Ecteinascidin 743,NSC-684766,ET-743)
- Trabectedin, >95%
- Trabectedin(Ecteinascidin 743,NSC-684766,ET-743, Yondelis)
- cteinascidin
- Ver más sinónimos
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Encontrado 6 productos.
Ref: IN-DA008TKA
1gA consultar1mg180,00€5mg589,00€10mg626,00€25mgA consultar50mgA consultar250mgA consultarTrabectedin
CAS:<p>Trabectedin (Ecteinascidin 743) has potent antitumor activity and the potential for soft tissue sarcoma and ovarian cancer research.</p>Fórmula:C39H43N3O11SPureza:≥98%Forma y color:SolidPeso molecular:761.84Trabectedin
CAS:Producto controlado<p>Applications A tetrahydroisoquinoline alkaloid with antitumor activity isolated from the Caribbean tunicate, Ecteinascidin turbinata. It is the first marine anticancer agent approved in the European Union for patients with soft tissue sarcoma (STS). Antineoplastic.<br>References Sakai, R., et al.: Proc. Natl. Acad. Sci., 89, 11456 (1992), Aune, G., et al.: Anticancer Drugs, 13, 545 (2002), Herrero, A., et al.: Cancer Res., 66, 8155 (2006), Sugasawa, K., et al.: Carcinogenesis, 29, 455 (2008),<br></p>Fórmula:C39H43N3O11SForma y color:NeatPeso molecular:761.84Trabectedin
CAS:<p>Trabectedin is a model system for investigating the role of protein genes in cancer. It is used for high throughput screening of potential biomarkers, such as blood sampling and mouse tumor models. Trabectedin has been shown to be a potent inhibitor of the p-gp substrate and has been used in vivo to treat cancers, including solid tumors and experimental models. This drug was also found to inhibit the antitumor response in normal human cells. Trabectedin is a taxane derivative that binds to the surface of cells with high affinity and prevents phosphorylation of proteins on the cell surface, which leads to inhibition of cell proliferation.</p>Fórmula:C39H43N3O11SPureza:Min. 95%Forma y color:White/Off-White SolidPeso molecular:761.84 g/mol





